Can Xencor, Inc. (XNCR)’s Tomorrow be Different? The Stock Formed a Bearish Wedge Down Pattern

Investors sentiment increased to 1.24 in Q4 2018. Its up 0.33, from 0.91 in 2018Q3. It improved, as 15 investors sold Xencor, Inc. shares while 30 reduced holdings. 17 funds opened positions while 39 raised stakes. 46.47 million shares or 1.24% more from 45.91 million shares in 2018Q3 were reported.
Bancorporation Of Mellon has 208,039 shares for 0% of their portfolio. The New York-based Tocqueville Asset Mngmt L P has invested 0% in Xencor, Inc. (NASDAQ:XNCR). Td Asset Mngmt Inc holds 0.01% or 134,903 shares. Us Bank & Trust De stated it has 43 shares. Jpmorgan Chase And, New York-based fund reported 246,162 shares. Manufacturers Life The accumulated 0% or 28,781 shares. The California-based Redmile Group Inc Limited Com has invested 4.48% in Xencor, Inc. (NASDAQ:XNCR). Rhenman Prtn Asset Mgmt Ab holds 0.9% or 218,537 shares. Moreover, State Of Wisconsin Inv Board has 0.01% invested in Xencor, Inc. (NASDAQ:XNCR). Bvf Il stated it has 2.8% of its portfolio in Xencor, Inc. (NASDAQ:XNCR). Zurcher Kantonalbank (Zurich Cantonalbank) reported 0% stake. Blackrock Incorporated owns 4.15M shares for 0.01% of their portfolio. The Japan-based Daiwa Secs Gp Inc has invested 0% in Xencor, Inc. (NASDAQ:XNCR). Arrowmark Colorado Limited Liability Company reported 0.17% of its portfolio in Xencor, Inc. (NASDAQ:XNCR). Ecor1 Cap Lc owns 989,018 shares or 3.58% of their US portfolio.

Since March 15, 2019, it had 3 buys, and 0 sales for $1.74 million activity.

The stock of Xencor, Inc. (XNCR) formed a down wedge with $30.17 target or 6.00 % below today’s $32.10 share price. The 7 months wedge indicates high risk for the $1.81B company. If the $30.17 price target is reached, the company will be worth $108.54 million less.
Falling wedges are poor performers for bullish breakouts and are tricky moments to trade. Investors must be aware that the break even failure rate for up or down breakouts is: 11% and 15%. The average rise is 32% and the decline is 15%. The falling wedges has high throwback and pullback rate: 56%, 69% and the percent of wedges meeting target is not very high.

The stock decreased 4.34% or $1.45 during the last trading session, reaching $32.1. About 60,045 shares traded. Xencor, Inc. (NASDAQ:XNCR) has risen 6.90% since May 8, 2018 and is uptrending. It has outperformed by 2.53% the S&P500.

Analysts await Xencor, Inc. (NASDAQ:XNCR) to report earnings on May, 9 after the close. They expect $0.43 EPS, up 169.35 % or $1.05 from last year’s $-0.62 per share. XNCR’s profit will be $24.23 million for 18.66 P/E if the $0.43 EPS becomes a reality. After $-0.32 actual EPS reported by Xencor, Inc. for the previous quarter, Wall Street now forecasts -234.38 % EPS growth.

Xencor, Inc. (NASDAQ:XNCR) Ratings Coverage

Among 7 analysts covering Xencor (NASDAQ:XNCR), 6 have Buy rating, 1 Sell and 0 Hold. Therefore 86% are positive. Xencor had 11 analyst reports since December 7, 2018 according to SRatingsIntel. Piper Jaffray maintained the shares of XNCR in report on Tuesday, February 26 with “Buy” rating. The stock of Xencor, Inc. (NASDAQ:XNCR) earned “Buy” rating by Cantor Fitzgerald on Wednesday, February 20. The firm has “Outperform” rating given on Friday, December 7 by Wedbush. The company was maintained on Thursday, March 21 by Nomura. On Tuesday, February 26 the stock rating was maintained by Cantor Fitzgerald with “Buy”. As per Tuesday, February 26, the company rating was maintained by Wedbush. The stock has “Buy” rating by Raymond James on Thursday, March 14.

More notable recent Xencor, Inc. (NASDAQ:XNCR) news were published by: which released: “May 08, 2019 – TD Asset Management Inc Buys Thomson Reuters Corp, Facebook Inc, iShares MSCI Emerging Index Fund, Sells Thomson Reuters Corp, CGI Inc, Allergan PLC –” on May 08, 2019, also with their article: “Here’s What Hedge Funds Think About Xencor Inc (XNCR) – Yahoo Finance” published on April 30, 2019, published: “3 Top Biotech Stocks to Buy Right Now – Motley Fool” on March 03, 2019. More interesting news about Xencor, Inc. (NASDAQ:XNCR) were released by: and their article: “Key events next week – healthcare – Seeking Alpha” published on November 23, 2018 as well as‘s news article titled: “Xencor (XNCR) Reports Pact on Novel IL-15 Immune Activating Cytokines with Genentech –” with publication date: February 05, 2019.

Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of engineered monoclonal antibodies to treat severe and life-threatening diseases with unmet medical needs. The company has market cap of $1.81 billion. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions. It currently has negative earnings. The company's product candidates include XmAb5871, an immune inhibitor, which is in Phase II clinical trials for the treatment of autoimmune diseases; XmAb7195, an immune inhibitor that is in Phase I clinical for use in treating asthma and allergic diseases; XmAb14045, a bispecific oncology candidate, which is in phase I clinical trials for the treatment of acute myeloid leukemia; and XmAb13676 that is in phase I clinical trials for the treatment of B-cell malignancies.

Xencor, Inc. (NASDAQ:XNCR) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.